# Puma Biotechnology, Inc.: financial statements, quarterly

PBYI · Nasdaq · CIK 1401667 · [Healthcare](/sectors/healthcare.md) · fiscal year ends Dec 31

Pages: [Overview](/companies/pbyi.md) · [Financials](/companies/pbyi/financials.md) · [Filings](/companies/pbyi/filings.md) · [Insiders](/companies/pbyi/insiders.md)

Standardized line items from XBRL company facts. Each value links to its filing; d marks a value derived from year-to-date figures. Other view: [annual](/companies/pbyi/financials.md?period=annual).

## Income statement

| Line item | Unit | Q3 FY2023 (2023-09-30) | Q4 FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Revenue | $m | [56.1](/filings/0001437749-24-033955.md) | [72.2 d](/filings/0001437749-26-005891.md) | [43.8](/filings/0001437749-25-015533.md) | [47.1](/filings/0001437749-25-025470.md) | [80.5](/filings/0001437749-25-033633.md) | [59.1 d](/filings/0001437749-26-005891.md) | [46.0](/filings/0001437749-26-015633.md) | [52.4](/filings/0001437749-26-026311.md) | [54.5](/filings/0001437749-25-033633.md) | [75.5 d](/filings/0001437749-26-005891.md) | [44.8](/filings/0001437749-26-015633.md) | [56.5](/filings/0001437749-26-026311.md) |
| Cost of revenue | $m | [13.3](/filings/0001437749-24-033955.md) | [24.3 d](/filings/0001437749-26-005891.md) | [10.7](/filings/0001437749-25-015533.md) | [10.7](/filings/0001437749-25-025470.md) | [29.1](/filings/0001437749-25-033633.md) | [13.9 d](/filings/0001437749-26-005891.md) | [10.6](/filings/0001437749-26-015633.md) | [12.3](/filings/0001437749-26-026311.md) | [12.2](/filings/0001437749-25-033633.md) | [23.1 d](/filings/0001437749-26-005891.md) | [10.4](/filings/0001437749-26-015633.md) | [12.5](/filings/0001437749-26-026311.md) |
| Research and development | $m | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |
| Selling, general and administrative | $m | [22.8](/filings/0001437749-24-033955.md) | [20.2 d](/filings/0001437749-26-005891.md) | [21.8](/filings/0001437749-25-015533.md) | [25.0](/filings/0001437749-25-025470.md) | [16.8](/filings/0001437749-25-033633.md) | [16.6 d](/filings/0001437749-26-005891.md) | [17.6](/filings/0001437749-26-015633.md) | [18.0](/filings/0001437749-26-026311.md) | [16.8](/filings/0001437749-25-033633.md) | [18.4 d](/filings/0001437749-26-005891.md) | [18.4](/filings/0001437749-26-015633.md) | [17.5](/filings/0001437749-26-026311.md) |
| Operating income | $m | [8.6](/filings/0001437749-24-033955.md) | [14.8 d](/filings/0001437749-26-005891.md) | [(2.3)](/filings/0001437749-25-015533.md) | [(2.2)](/filings/0001437749-25-025470.md) | [22.1](/filings/0001437749-25-033633.md) | [13.4 d](/filings/0001437749-26-005891.md) | [4.0](/filings/0001437749-26-015633.md) | [6.6](/filings/0001437749-26-026311.md) | [9.6](/filings/0001437749-25-033633.md) | [17.1 d](/filings/0001437749-26-005891.md) | [(3.8)](/filings/0001437749-26-015633.md) | [7.6](/filings/0001437749-26-026311.md) |
| Interest expense | $m | [3.3](/filings/0001437749-23-030028.md) | [3.4 d](/filings/0001437749-24-006121.md) | [3.4](/filings/0001437749-24-014395.md) | [3.4](/filings/0001437749-25-025470.md) | [3.1](/filings/0001437749-25-033633.md) | [2.6 d](/filings/0001437749-26-005891.md) | [2.2](/filings/0001437749-26-015633.md) | [1.8](/filings/0001437749-26-026311.md) | [1.5](/filings/0001437749-25-033633.md) | [1.1 d](/filings/0001437749-26-005891.md) | [0.7](/filings/0001437749-26-015633.md) | [0.2](/filings/0001437749-26-026311.md) |
| Income tax | $m | [0.2](/filings/0001437749-24-033955.md) | [0.5 d](/filings/0001437749-26-005891.md) | [0.2](/filings/0001437749-24-014395.md) | [0.4](/filings/0001437749-24-024309.md) | [0.3](/filings/0001437749-24-033955.md) | [(7.1) d](/filings/0001437749-26-005891.md) | not reported | not reported | not reported | not reported | not reported | not reported |
| Net income | $m | [5.8](/filings/0001437749-24-033955.md) | [12.3 d](/filings/0001437749-26-005891.md) | [(4.8)](/filings/0001437749-25-015533.md) | [(4.5)](/filings/0001437749-25-025470.md) | [20.3](/filings/0001437749-25-033633.md) | [19.3 d](/filings/0001437749-26-005891.md) | [3.0](/filings/0001437749-26-015633.md) | [5.9](/filings/0001437749-26-026311.md) | [8.8](/filings/0001437749-25-033633.md) | [13.4 d](/filings/0001437749-26-005891.md) | [(3.8)](/filings/0001437749-26-015633.md) | [8.2](/filings/0001437749-26-026311.md) |
| Diluted EPS | $ per share | [0.12](/filings/0001437749-24-033955.md) | not reported | [(0.10)](/filings/0001437749-25-015533.md) | [(0.09)](/filings/0001437749-25-025470.md) | [0.41](/filings/0001437749-25-033633.md) | not reported | [0.06](/filings/0001437749-26-015633.md) | [0.12](/filings/0001437749-26-026311.md) | [0.17](/filings/0001437749-25-033633.md) | not reported | [(0.07)](/filings/0001437749-26-015633.md) | [0.16](/filings/0001437749-26-026311.md) |
| Basic EPS | $ per share | [0.12](/filings/0001437749-24-033955.md) | not reported | [(0.10)](/filings/0001437749-25-015533.md) | [(0.09)](/filings/0001437749-25-025470.md) | [0.41](/filings/0001437749-25-033633.md) | not reported | [0.06](/filings/0001437749-26-015633.md) | [0.12](/filings/0001437749-26-026311.md) | [0.18](/filings/0001437749-25-033633.md) | not reported | [(0.07)](/filings/0001437749-26-015633.md) | [0.16](/filings/0001437749-26-026311.md) |

- Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
- Cost of revenue: us-gaap:CostOfGoodsAndServicesSold
- Research and development: not reported
- Selling, general and administrative: us-gaap:SellingGeneralAndAdministrativeExpense
- Operating income: us-gaap:OperatingIncomeLoss
- Interest expense: us-gaap:InterestExpense, us-gaap:InterestExpenseNonoperating
- Income tax: us-gaap:IncomeTaxExpenseBenefit
- Net income: us-gaap:NetIncomeLoss
- Diluted EPS: us-gaap:EarningsPerShareDiluted
- Basic EPS: us-gaap:EarningsPerShareBasic

## Balance sheet

| Line item | Unit | Q3 FY2023 (2023-09-30) | FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Cash and equivalents | $m | [81.8](/filings/0001437749-23-030028.md) | [84.6](/filings/0001437749-25-005496.md) | [76.8](/filings/0001437749-24-014395.md) | [67.1](/filings/0001437749-24-024309.md) | [67.3](/filings/0001437749-24-033955.md) | [69.2](/filings/0001437749-26-005891.md) | [63.0](/filings/0001437749-25-015533.md) | [54.7](/filings/0001437749-25-025470.md) | [53.5](/filings/0001437749-25-033633.md) | [29.6](/filings/0001437749-26-026311.md) | [36.2](/filings/0001437749-26-015633.md) | [36.5](/filings/0001437749-26-026311.md) |
| Current assets | $m | [125](/filings/0001437749-23-030028.md) | [156](/filings/0001437749-25-005496.md) | [143](/filings/0001437749-24-014395.md) | [138](/filings/0001437749-24-024309.md) | [157](/filings/0001437749-24-033955.md) | [148](/filings/0001437749-26-005891.md) | [133](/filings/0001437749-25-015533.md) | [137](/filings/0001437749-25-025470.md) | [144](/filings/0001437749-25-033633.md) | [163](/filings/0001437749-26-026311.md) | [142](/filings/0001437749-26-015633.md) | [145](/filings/0001437749-26-026311.md) |
| Total assets | $m | [204](/filings/0001437749-23-030028.md) | [231](/filings/0001437749-25-005496.md) | [214](/filings/0001437749-24-014395.md) | [205](/filings/0001437749-24-024309.md) | [221](/filings/0001437749-24-033955.md) | [213](/filings/0001437749-26-005891.md) | [196](/filings/0001437749-25-015533.md) | [195](/filings/0001437749-25-025470.md) | [203](/filings/0001437749-25-033633.md) | [216](/filings/0001437749-26-026311.md) | [193](/filings/0001437749-26-015633.md) | [193](/filings/0001437749-26-026311.md) |
| Current liabilities | $m | [67.4](/filings/0001437749-23-030028.md) | [99.4](/filings/0001437749-25-005496.md) | [98.2](/filings/0001437749-24-014395.md) | [104](/filings/0001437749-24-024309.md) | [110](/filings/0001437749-24-033955.md) | [96.1](/filings/0001437749-26-005891.md) | [86.7](/filings/0001437749-25-015533.md) | [79.1](/filings/0001437749-25-025470.md) | [82.7](/filings/0001437749-25-033633.md) | [81.3](/filings/0001437749-26-026311.md) | [59.7](/filings/0001437749-26-015633.md) | [49.8](/filings/0001437749-26-026311.md) |
| Total liabilities | $m | [165](/filings/0001437749-23-030028.md) | [177](/filings/0001437749-25-005496.md) | [163](/filings/0001437749-24-014395.md) | [156](/filings/0001437749-24-024309.md) | [150](/filings/0001437749-24-033955.md) | [121](/filings/0001437749-26-005891.md) | [99.1](/filings/0001437749-25-015533.md) | [90.2](/filings/0001437749-25-025470.md) | [87.6](/filings/0001437749-25-033633.md) | [86.0](/filings/0001437749-26-026311.md) | [64.3](/filings/0001437749-26-015633.md) | [54.2](/filings/0001437749-26-026311.md) |
| Long-term debt | $m | [76.6](/filings/0001437749-23-030028.md) | [65.7](/filings/0001437749-25-005496.md) | [54.7](/filings/0001437749-24-014395.md) | [43.7](/filings/0001437749-24-024309.md) | [32.7](/filings/0001437749-24-033955.md) | [21.7](/filings/0001437749-26-005891.md) | [10.6](/filings/0001437749-25-015533.md) | [10.9](/filings/0001437749-25-025470.md) | [0.0](/filings/0001437749-25-033633.md) | [0.0](/filings/0001437749-26-005891.md) | [0.0](/filings/0001437749-26-015633.md) | [0.0](/filings/0001437749-26-026311.md) |
| Current portion of debt | $m | [22.7](/filings/0001437749-23-030028.md) | [34.0](/filings/0001437749-25-005496.md) | [45.3](/filings/0001437749-24-014395.md) | [45.3](/filings/0001437749-24-024309.md) | [45.3](/filings/0001437749-24-033955.md) | [45.3](/filings/0001437749-26-005891.md) | [45.3](/filings/0001437749-25-015533.md) | [34.0](/filings/0001437749-25-025470.md) | [33.7](/filings/0001437749-25-033633.md) | [22.5](/filings/0001437749-26-026311.md) | [11.3](/filings/0001437749-26-015633.md) | [0.0](/filings/0001437749-26-026311.md) |
| Shareholders' equity | $m | [38.7](/filings/0001437749-24-033955.md) | [53.4](/filings/0001437749-26-005891.md) | [51.0](/filings/0001437749-25-025470.md) | [48.5](/filings/0001437749-25-033633.md) | [71.1](/filings/0001437749-25-033633.md) | [92.1](/filings/0001437749-26-026311.md) | [97.1](/filings/0001437749-26-026311.md) | [105](/filings/0001437749-26-026311.md) | [115](/filings/0001437749-25-033633.md) | [130](/filings/0001437749-26-026311.md) | [128](/filings/0001437749-26-026311.md) | [139](/filings/0001437749-26-026311.md) |

- Cash and equivalents: us-gaap:CashAndCashEquivalentsAtCarryingValue
- Current assets: us-gaap:AssetsCurrent
- Total assets: us-gaap:Assets
- Current liabilities: us-gaap:LiabilitiesCurrent
- Total liabilities: us-gaap:Liabilities
- Long-term debt: us-gaap:LongTermDebtNoncurrent
- Current portion of debt: us-gaap:LongTermDebtCurrent
- Shareholders' equity: us-gaap:StockholdersEquity

## Cash flow

| Line item | Unit | Q3 FY2023 (2023-09-30) | Q4 FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Operating cash flow | $m | [10.6 d](/filings/0001437749-24-033955.md) | [10.5 d](/filings/0001437749-26-005891.md) | [11.2](/filings/0001437749-25-015533.md) | [1.0 d](/filings/0001437749-25-025470.md) | [11.0 d](/filings/0001437749-25-033633.md) | [15.6 d](/filings/0001437749-26-005891.md) | [3.6](/filings/0001437749-26-015633.md) | [14.1 d](/filings/0001437749-26-026311.md) | [9.7 d](/filings/0001437749-25-033633.md) | [14.4 d](/filings/0001437749-26-005891.md) | [15.4](/filings/0001437749-26-015633.md) | [1.6 d](/filings/0001437749-26-026311.md) |
| Capital expenditure | $m | [0.0 d](/filings/0001437749-24-033955.md) | [0.0 d](/filings/0001437749-26-005891.md) | [0.0](/filings/0001437749-25-015533.md) | [0.0 d](/filings/0001437749-25-025470.md) | [0.0 d](/filings/0001437749-25-033633.md) | [0.0 d](/filings/0001437749-26-005891.md) | [0.1](/filings/0001437749-26-015633.md) | [0.0 d](/filings/0001437749-26-026311.md) | [0.0 d](/filings/0001437749-25-033633.md) | [(0.0) d](/filings/0001437749-26-005891.md) | [0.0](/filings/0001437749-26-015633.md) | [0.0 d](/filings/0001437749-26-026311.md) |

- Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities
- Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment

## Shares

| Line item | Unit | Q3 FY2022 (2022-09-30) | Q1 FY2023 (2023-03-31) | Q2 FY2023 (2023-06-30) | Q3 FY2023 (2023-09-30) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Diluted shares (weighted) | millions of shares | [45.6](/filings/0001437749-23-030028.md) | [47.2](/filings/0001437749-24-014395.md) | [47.2](/filings/0001437749-24-024309.md) | [47.8](/filings/0001437749-24-033955.md) | [48.2](/filings/0001437749-25-015533.md) | [48.3](/filings/0001437749-25-025470.md) | [49.2](/filings/0001437749-25-033633.md) | [49.9](/filings/0001437749-26-015633.md) | [50.1](/filings/0001437749-26-026311.md) | [50.9](/filings/0001437749-25-033633.md) | [50.8](/filings/0001437749-26-015633.md) | [52.6](/filings/0001437749-26-026311.md) |

- Diluted shares (weighted): us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding

Shares outstanding: 51,620,066 at 2026-08-03, from the cover of the [10-Q filed 2026-08-06](/filings/0001437749-26-026311.md) (dei:EntityCommonStockSharesOutstanding).

Source: SEC EDGAR, XBRL company facts. Last ingested by Listed: Oct 24, 2026, 15:38 ET. No prices; not investment advice.